Moderna's Revenue Growth Driven by COVID Products Raises Valuation Concerns
Moderna reported third-quarter revenue of nearly $1.3 billion, exceeding expectations and prompting the company to raise its full-year guidance to a 15%–25% growth range. However, despite the beat, approximately 98% of the company's total revenue remains tied to COVID-related products, with only a small fraction coming from its RSV vaccine. The market has reacted bullishly, driven largely by optimism surrounding a personalized cancer vaccine being developed in partnership with Merck. Despite positive clinical trial results, analysts warn that the stock's high valuation—with a market cap exceeding $100 billion—may not be justified given the lack of regulatory approval for new products and the significant operational hurdles involved in mass-producing personalized therapies.
Topics: COVID-19 vaccines earnings report guidance increase revenue growth
Read the full article at Motley Fool
Part of the story QuickLogic Reports 153% Year-Over-Year Revenue Growth Driven by New Products (2 articles)